BRIDGING HOPE AND INNOVATION
Transforming Your Health with Cord Blood Mononuclear Stem Cell Therapy
Connecting You to
World-Class Regenerative Treatments
At Cordlife, we understand that the journey to better health - and especially to parenthood is deeply personal. Cordlife Stem Cell Therapy Concierge Service is dedicated to supporting individuals and families seeking advanced, science-backed stem cell therapies in China for both reproductive health and a range of chronic conditions. With compassionate, expert-guided care at every stage, we take the stress out of navigating overseas treatment so you can focus on what matters most: healing and hope.
Powered by Partnership and Innovation
In partnership with a renowned stem cell banking and therapy provider in China, Cordlife connects you to world-leading experts and institutions equipped with cutting-edge technologies. These collaborations allow us to deliver evidence-based, ethically conducted therapies that are at the forefront of regenerative medicine. Each treatment plan is developed in consultation with specialists in stem cell research, reproductive medicine, and chronic disease care - ensuring that your unique needs are respected, understood, and met with medical excellence.
REGENERATIVE THERAPY WITH UMBILICAL CORD BLOOD MONONUCLEAR CELLS
A Natural Healing Approach for Chronic & Degenerative Conditions
WOMEN'S HEALTH THROUGH REGENERATIVE THERAPY
Harnessing the Power of Umbilical Cord Blood MNCs for Natural Healing and Vitality
What is Premature Ovarian Failure (POF)?
POF is defined by the cessation of normal ovarian function before the age of 40. The condition is characterized by the depletion of ovarian follicles leading to loss both of germinative and hormonal functions prior to the typical age for physiological menopause.<br /> Common symptoms include secondary amenorrhea, infertility, and perimenopausal symptoms such as vasomotor disturbances (e.g., night sweats), insomnia, and cognitive changes including memory decline.1 The condition is believed to result from a combination of premature follicular depletion, autoimmune ovarian damage, and underlying genetic predisposition. POF affects approximately 1% of women, with an incidence of 1 in 100 before the age of 40, and 1 in 1,000 before the age of 30.
Therapeutic Mechanism & Cord Blood MNCs Contribution
ANGIOGENESIS
Stimulate the formation of new blood vessels, increasing ovarian blood flow by 30-40%, this provides vital oxygen and nutrients to support tissue repair.
HORMONAL REGULATION
Supports the restoration of natural ovarian hormone secretion, especially estrogen, to help rebalance reproductive hormones.
ANTI-APOPTOSIS
Protects and preserves ovarian cells, particularly granulosa cells, to support follicle health and enhance fertility potential.
ANTI-INFLAMMATION
Reduces inflammatory T cells and NK cells, boosts Treg cells, and lowers ovarian inflammation markers by 40–50%, promoting ovarian healing and recovery.
Therapy Options
INTRAVENOUS INFUSION
3 sessions at 1-month interval
OVARIAN TARGETED INFUSION
Ultrasound-guided ovarian infusion
INTRA-ARTERIAL INFUSION
Under anesthesia, small tubes were inserted in the thigh to access ovarian blood vessels
What is Recurrent Implantation Failure (RIF)?
RIF is defined as the failure to achieve a clinical pregnancy after three or more in vitro fertilization–embryo transfer (IVF-ET) cycles, despite the transfer of at least four high-quality cleavage-stage embryos. After excluding factors such as maternal psychological issues, anatomical abnormalities, endometrial dysfunction, thrombophilia, embryonic genetic defects, and poor embryo development, the cause of RIF often remains unclear. Immune system dysregulation is also considered as a potential underlying factor. Studies suggest that RIF patients may fail to recruit the necessary lymphocytes for embryo implantation, as such intrauterine perfusion of MNCs may help restore immune balance and improve implantation rates.
Therapeutic Mechanism & Cord Blood MNCs Contribution
ENHANCES ENDOMETRIAL RECEPTIVITY
Promotes a thicker, healthier endometrial lining to improve embryo attachment and implantation success.
SUPPORTS EARLY PLACENTAL DEVELOPMENT
Encourages trophoblast cell activity to aid in forming a robust placental barrier and modulate immune responses.
Therapy Options
OVARIAN TARGETED INFUSION
2 sessions of Ultrasound-guided ovarian infusion
• 1st infusion: 3-7 days after menstruation ends
• 2nd infusion: 1 week before embryo implantation
What is Thin Endometrium (TE)?
TE is defined as a mid-luteal endometrial thickness ≤7mm. TE can affect endometrial tolerance, leading to lower embryo implantation rates and clinical pregnancy rates, and is also associated with impaired outcomes from assisted reproductive treatment. Thin endometrium is a major cause of female infertility, and severe endometrial damage is often irreversible.
Therapeutic Mechanism & Cord Blood MNCs Contribution
STIMULATES TISSUE
GROWTH
Boosts angiogenesis and endothelial proliferation, leading to endometrial thickening.
REVERSES FIBROTIC
DAMAGE
Reduces scarring and improves structural integrity of the endometrial tissue.
ENHANCES LOCAL HEALING
ENVIRONMENT
Alleviates inflammation to support regeneration and receptivity.
Therapy Options
INTRAUTERINE INFUSION
2 sessions of intrauterine infusion
• 1st infusion: 3-7 days after menstruation ends
• 2nd infusion: 1 week before embryo implantation
POST-HYSTEROSCOPIC ADHESION
Intramyometrial injection
What is Intrauterine Adhesion (IUA)?
Intrauterine Adhesion (IUA), also known as Asherman's Syndrome, is a condition where scar tissue forms inside the uterus, often after procedures like dilation and curettage (D&C), uterine surgery, or infections. These adhesions can partially or completely block the uterine cavity, leading to symptoms such as light or absent menstrual periods, infertility, recurrent miscarriages, and pelvic pain. IUA may significantly affect a woman’s reproductive health, increasing the risk of complications such as recurrent pregnancy loss, abnormal placental attachment, preterm birth, and postpartum hemorrhage, especially when left unrecognized or untreated. Early attention to symptoms is crucial for reproductive outcomes.
Therapeutic Mechanism & Cord Blood MNCs Contribution
CLEARS FIBROTIC
TISSUE
Promotes enzymatic and cellular activity to help clear intrauterine debris and scar tissue.
REDUCES
INFLAMMATION
Creates a balanced immune environment that supports uterine healing and prevents adhesion recurrence.
ACTIVATES GROWTH FACTOR
RELEASE
Triggers release of VEGF and FGF to encourage blood vessel and tissue regeneration.
Therapy Options
INTRAUTERINE INFUSION
1 session of Ultrasound-guided ovarian infusion
What is Endometriosis?
Endometriosis is a chronic condition where tissue similar to the uterine lining grows outside the uterus, commonly on the ovaries, fallopian tubes, and other pelvic organs. This tissue responds to hormonal changes during the menstrual cycle, causing inflammation, pain, and internal bleeding. Since the tissue has no way to exit the body, it can lead to scarring, adhesions, and in some cases, infertility. Symptoms often include severe menstrual cramps, pelvic pain, and pain during sex or bowel movements. Diagnosis typically requires laparoscopy, and treatment options include pain relief, hormonal therapy, and surgery to remove the abnormal tissue growths.
Therapeutic Mechanism & Cord Blood MNCs Contribution
PROMOTES TISSUE
REPAIR
Encourages regeneration of healthy endometrial tissue and reduces abnormal tissue growth.
CONTROLS INFLAMMATORY
RESPONSE
Modulates the immune system to reduce chronic inflammation and oxidative stress.
BALANCES HORMONAL &
IMMUNE ACTIVITY
Helps restore equilibrium in hormonal cycles and immune tolerance to reduce recurrence and symptoms.
Therapy Options
INTRAUTERINE INFUSION
1 session, 1 week before embryo transfer
GENERAL HEALTH THROUGH REGENERATIVE THERAPY
Innovative Therapies for Long-Term Health & Mobility
What is Knee Osteoarthritis (KOA)?
Knee osteoarthritis (KOA) is a progressive degenerative joint disorder characterized by the breakdown of articular cartilage and changes in subchondral bone in the knee joint. It leads to joint pain, stiffness, swelling, decreased function, and reduced quality of life. Risk factors include aging, obesity, previous joint injuries, repetitive stress, and genetic predisposition. Although there is no cure, treatment options such as physical therapy, weight management, medications, intra-articular injections, and surgical interventions aim to relieve symptoms and improve joint function.
Therapeutic Mechanism & Cord Blood MNCs Contribution
CARTILAGE REGENERATION
Promotes chondrocyte proliferation and extracellular matrix repair, aiding in the
regeneration of joint cartilage.
INFLAMMATION MODULATION
Suppresses inflammatory mediators reducing joint swelling and pain.
ANTI-APOPTOSIS
Prevents programmed death of chondrocytes, helping preserve joint structure
and delay disease progression.
Therapy Options
INJECTION INTO JOINT CAVITY
3 sessions at 2-weeks interval
What is Ulcerative Colitis (UC)?
Ulcerative colitis (UC) is a long-term inflammatory condition affecting the inner lining of the large intestine (colon) and rectum. It causes continuous inflammation and ulcers—small sores that can bleed and produce pus. This disrupts bowel function, leading to persistent diarrhea often mixed with blood or mucus, abdominal pain, cramping, urgency to defecate, rectal bleeding, fatigue, and weight loss. The exact cause is unclear but believed to result from an abnormal immune response attacking intestinal tissues. Genetics and environmental factors like infections or diet may contribute. The disease develops gradually, with flare-ups and remissions. Chronic inflammation can cause complications like colon lining damage or increased cancer risk, requiring ongoing monitoring.
Therapeutic Mechanism & Cord Blood MNCs Contribution
MUCOSAL HEALING &
ULCER REPAIR
Stimulates epithelial cell turnover and accelerates closure of ulcerated tissue in the colon.
IMMUNE MODULATION
Shifts T cell balance toward regulatory phenotypes (e.g. Treg cells) while suppressing overactive immune responses.
INFLAMMATION SUPPRESSION
Reduces inflammatory cytokines alleviating mucosal damage and clinical symptoms.
REDUCTION OF
INFLAMMATORY CELL INFILTRATION
Minimizes migration of immune cells like neutrophils and macrophages into the colonic tissue, easing disease activity.
Therapy Options
INFERIOR MESENTERIC ARTERY
1 session
What is Membranous Nephropathy (MN)?
Membranous nephropathy (MN) is a kidney disorder characterized by thickening of the glomerular basement membrane due to immune complex deposits. It commonly presents with nephrotic syndrome, which includes symptoms such as high levels of protein in the urine (proteinuria), low blood albumin, swelling (edema), and elevated cholesterol. MN can be classified as primary (often autoimmune, involving antibodies to the PLA2R antigen) or secondary, caused by infections, autoimmune diseases, cancer, or certain medications. Diagnosis is confirmed through blood tests, urine analysis, and kidney biopsy. The prognosis varies, with some patients experiencing spontaneous remission, while others may<br /> progress to chronic kidney disease.
Therapeutic Mechanism & Cord Blood MNCs Contribution
RENAL
REGENERATION
Stimulates differentiation of stem-like cells into functional renal parenchymal cells, supporting nephron repair.
IMMUNE REBALANCING
Modulates autoreactive immune responses, including B and T cell activity, to reduce glomerular immune complex deposition.
ANTI-INFLAMMATORY &
ANTIOXIDANT ACTION
Mitigates oxidative stress and renal inflammation, protecting kidney tissue from further damage.
ANTI-FIBROTIC
REPAIR
Inhibits Transforming Growth Factor-β signaling to reduce renal scarring and preserve long-term kidney function.
Therapy Options
INTRAVENOUS INFUSION
3 sessions at 3 weeks interval
If rituximab treatment is administered, MNC infusion should be given four weeks later
What is Frailty Syndrome?
Frailty Syndrome is a clinical condition commonly seen in older adults, characterized by reduced strength, endurance, and physiological function, increasing vulnerability to stressors like illness or falls. It often presents with symptoms such as unintentional weight loss, weakness, fatigue, slow walking speed, and low physical activity. Pre-frailty is an intermediate stage where one or two of these symptoms are present, signaling a heightened risk of progressing to full frailty if not addressed. Recognizing and treating frailty is essential for improving quality of life and reducing hospitalizations and mortality in aging populations.
Therapeutic Mechanism & Cord Blood MNCs Contribution
TISSUE REGENERATION
Promotes muscle fiber repair and enhances cellular metabolism in skeletal and soft tissues.
PHYSICAL PERFORMANCE
ENHANCEMENT
Improves gait speed, grip strength, and mobility via vascular support and neuroendocrine regulation.
SYSTEMIC INFLAMMATION
REDUCTION
Downregulates chronic inflammatory markers (e.g. CRP, IL-6), which contribute to physical and cognitive decline.
IMMUNE SYSTEM
REJUVENATION
Supports hematopoietic balance and immune cell homeostasis, improving resilience against infections and metabolic stress.
Therapy Options
INTRAVENOUS INFUSION
2 sessions at 1 month interval
CORDLIFE CONCIERGE SERVICES
